Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives
Journal of Neurochemistry · 2023-06 · 165 (6) · 772-790
DOI: 10.1111/jnc.15824 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neurochemistry, online erschienen am 26.04.2023. Verfasst von Fei Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Chitinases, Neurodegenerative Diseases, Brain Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Project of Shaanxi Provincial Administration of Traditional Chinese Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chitinase‐3‐like protein 1 (CHI3L1) is a secreted glycoprotein characterized by its ability to regulate multiple biological processes, such as the inflammatory response and gene transcriptional signaling activation. Abnormal CHI3L1 expression has been associated with multiple neurological disorders and serves as a biomarker for the early detection of several neurodegenerative diseases. Aberrant CHI3L1 expression is also reportedly associated with brain tumor migration and metastasis, as well as contributions to immune escape, playing important roles in brain tumor progression. CHI3L1 is synthesized and secreted mainly by reactive astrocytes in the central nervous system. Thus, targeting astrocytic CHI3L1 could be a promising approach for the treatment of neurological diseases, such as traumatic brain injury, ischemic stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and glioma. Based on current knowledge of CHI3L1, we assume that it acts as a molecule mediating several signaling pathways driving the initiation and progression of neurological disorders. This narrative review is the first to introduce the potential roles of astrocytic CHI3L1 in neurological disorders. We also equally explore astrocytic CHI3L1 mRNA expression under physiological and pathological conditions. Inhibiting CHI3L1 and disrupting its interaction with its receptors through multiple mechanisms of action are briefly discussed. These endeavors highlight the pivotal roles of astrocytic CHI3L1 in neurological disorders and could contribute to the development of effective inhibitors based on the strategy of structure‐based drug discovery, which could be an attractive therapeutic approach for neurological disease treatment. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Pharmacy, The Hospital of 92880 Troops, PLA Navy, Zhoushan, Zhejiang, China.
- Institute of Medical Research, Northwestern Polytechnical University, Shaanxi, Xi'an, China.
ORCID-Profile: Fei Li, An Liu, Minggao Zhao, Lanxin Luo
Förderung
- Project of Shaanxi Provincial Administration of Traditional Chinese Medicine
- National Natural Science Foundation of China
Zitieren
APA
Li, F., Liu, A., Zhao, M., & Luo, L. (2023). Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives. Journal of Neurochemistry, 165(6), 772-790. https://doi.org/10.1111/jnc.15824
Vancouver
Li F, Liu A, Zhao M, Luo L. Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives. Journal of Neurochemistry. 2023;165(6):772-790. doi:10.1111/jnc.15824
BibTeX
@article{Li2023,
author = {Li, Fei and Liu, An and Zhao, Minggao and Luo, Lanxin},
title = {Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives},
journal = {Journal of Neurochemistry},
year = {2023},
volume = {165},
number = {6},
pages = {772--790},
doi = {10.1111/jnc.15824}
}
EUVIMED